RANCHO
CORDOVA, Calif., July 17,
2023 /PRNewswire/ -- ThermoGenesis Holdings, Inc.
(Nasdaq: THMO), a market leader in automated cell processing tools
and services in the cell and gene therapy field, today
announced the appointments of Biao Xi, Ph.D. and James Xu, Esq., DBA, PsyD., J.D., CPA to its
Board, effective July 17, 2023. Both
are independent directors. The appointments expand ThermoGenesis'
Board to seven members.
"Biao is a highly regarded life science executive with extensive
experience in biopharmaceutical research and drug development and
James brings strong legal and business acumen, including more than
25 years in the field of patent, corporate and tax law. Together,
their expertise will significantly strengthen our Board of
Directors," stated Chris Xu, Ph.D.,
Chief Executive Officer of ThermoGenesis. "I look forward to
leveraging their valuable insights as we continue to transition
into a high performance, integrated contract development and
manufacturing organization (CDMO) in the cell and gene therapy
field and as we continue to draw interest from early-stage life
science and cell and gene therapy companies for our turnkey
ReadyStart cGMP Suites, which we expect to be available in the
third quarter of this year."
Since March 2022, Dr. Xi has
served as Chief Scientific Officer, Co-founder, and member of the
Board of Miracure Biotechnology, a San
Diego based, early-stage drug discovery company developing
new drug candidates for oncology and immunology applications. From
2018 to 2021, Dr. Xi served as Chief Executive Officer at
ImmunePoint Inc. and Vice President of Translational Study at
Theragene Pharmaceuticals. From 2006 to 2018, he was Chief
Scientist for China at ACEA
Biosciences, an Agilent company. Dr. Xi was a Research Assistant
Professor at Albert Einstein College of Medicine from 1999 through
2006. He earned a master's degree from the Chinese Academy of
Sciences and a Ph.D from Zhejiang
University in China.
Dr. Xu is a practicing attorney and licensed CPA in the
State of Illinois. He is also
a Patent Lawyer licensed by United States Patent and
Trademark Office and has been practicing patent, corporate and tax
law for more than 25 years. Previously, from November 2016 to December
2019, Dr. Xu served as a member of ThermoGenesis Holdings,
Inc.'s Board of Directors and was a member of the X committee. Dr.
Xu received a Master of Science in Electrical Engineering and an
MBA from the University of Mississippi,
J.D. and LLM degrees in Taxation from DePaul Law School, an LLM in Intellectual
Properties and LLM in Information Technologies from John Marshall Law School, a Psy.D. from
California Southern University, and a
DBA from University of Missouri-St.
Louis.
About ThermoGenesis Holdings, Inc.
ThermoGenesis Holdings, Inc. develops, commercializes, and
markets a range of automated technologies for CAR-T and other
cell-based therapies. The Company currently markets a full suite of
solutions for automated clinical biobanking, point-of-care
applications, and automation for immuno-oncology, including its
semi-automated, functionally closed CAR-TXpress™ platform, which
streamlines the manufacturing process for the emerging CAR-T
immunotherapy market. For more information about ThermoGenesis,
please visit: www.thermogenesis.com.
Forward-Looking Statements
This press release contains "forward-looking statements" within
the meaning of the U.S. Private Securities Litigation Reform Act of
1995. The forward-looking statements involve risks and
uncertainties that could cause actual results to differ materially
from the forward-looking statements contained herein. When used in
this press release, the words "anticipate," "believe," "estimate,"
"expect" and similar expressions as they relate to the Company, or
its management are intended to identify such forward-looking
statements. Actual results, performance or achievements could
differ materially from the results expressed in or implied by these
forward-looking statements. Readers should be aware of important
factors that, in some cases, have affected, and in the future could
affect, actual results to differ materially from those expressed in
any forward-looking statements made by or on behalf of the Company.
These factors include without limitation, the ability to obtain
capital and other financing in the amounts and at the times needed
to launch new products and grow our CDMO business, market
acceptance of new products, the nature and timing of regulatory
approvals for both new products and existing products for which the
Company proposes new claims, realization of forecasted revenues,
expenses and income, initiatives by competitors, price pressures,
failure to meet FDA regulated requirements governing the Company's
products and operations (including the potential for product
recalls associated with such regulations), risks associated with
initiating manufacturing for new products, failure to meet Foreign
Corrupt Practice Act regulations, legal proceedings, risks
associated with expanding into the Company's planned CDMO business,
uncertainty associated with the COVID-19 pandemic, and other risk
factors listed from time to time in our reports with the Securities
and Exchange Commission ("SEC"), including, in particular, those
set forth in ThermoGenesis Holdings' Form 10-K for the year ended
December 31, 2022.
Company Contact:
Wendy Samford
916-858-5191
ir@ThermoGenesis.com
Investor Contact:
Paula Schwartz, Rx Communications
917-322-2216
pschwartz@rxir.com
View original
content:https://www.prnewswire.com/news-releases/thermogenesis-expands-board-of-directors-with-the-appointments-of-dr-biao-xi-and-dr-james-xu-301878779.html
SOURCE ThermoGenesis Holdings, Inc.